Emergence of SARS-CoV-2 Escape Mutations during Bamlanivimab Therapy in a Phase II Randomized Clinical Trial

Scientists reported that treatment-emergent resistance mutations were significantly more likely to be detected after bamlanivimab 700 mg treatment compared with the placebo group.